{"title":"CK19在甲状腺乳头状癌和甲状腺良性病变中的表达","authors":"Thura Abbas Fadhel","doi":"10.26505/djm.v24i1.972","DOIUrl":null,"url":null,"abstract":"Background: The Papillary variant of thyroid carcinoma is one of the common types of thyroid malignancies , the commonest. Its diagnosis usually is microscopic which based on nuclear features. \nObjective: To assess the immunohistochemical expression of cytokeratin 19 (CK19) in PTC and compare its reactivity with other thyroid conditions to approve its importance as a useful test for diagnosing PTC. \nPatients and Methods: Twenty- cases of papillary thyroid carcinoma (with different variants), five follicular adenomas and ten multinodular goiters (MNG) were collected over three years (2018-2021).10% formalin-fixed sections were collected from thyroidectomy specimens. Stained with Hematoxylin and eosin then immunohistochemical staining for immune-marker CK 19 was done using standard techniques. The results were quantitatively scored as the following: score 0 (negative ), score 1+ (<5%) positive cells), score 2+ (5- 25%), score 3+ (25-75%) ,finally score 4+ (>75%) positive cells), and then calculated. \nResults: An 18 (90%) papillary carcinomas show diffuse and strong (3+ and 4+) expression of CK19 . ,three out of ten (30%) MNG were weakly positive(1+ and 2+) and focal in distribution while in follicular adenoma all cases were negative for CK19 . \nConclusion: Ck 19 can stain benign and malignant thyroid tissue, but strong membranous staining applied in cases of papillary ca , thus can be used as confirmatorytool for PTC diagnosis.","PeriodicalId":11202,"journal":{"name":"Diyala Journal of Medicine","volume":"90 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression of CK19 in papillary thyroid carcinoma in comparison with benign thyroid lesions\",\"authors\":\"Thura Abbas Fadhel\",\"doi\":\"10.26505/djm.v24i1.972\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: The Papillary variant of thyroid carcinoma is one of the common types of thyroid malignancies , the commonest. Its diagnosis usually is microscopic which based on nuclear features. \\nObjective: To assess the immunohistochemical expression of cytokeratin 19 (CK19) in PTC and compare its reactivity with other thyroid conditions to approve its importance as a useful test for diagnosing PTC. \\nPatients and Methods: Twenty- cases of papillary thyroid carcinoma (with different variants), five follicular adenomas and ten multinodular goiters (MNG) were collected over three years (2018-2021).10% formalin-fixed sections were collected from thyroidectomy specimens. Stained with Hematoxylin and eosin then immunohistochemical staining for immune-marker CK 19 was done using standard techniques. The results were quantitatively scored as the following: score 0 (negative ), score 1+ (<5%) positive cells), score 2+ (5- 25%), score 3+ (25-75%) ,finally score 4+ (>75%) positive cells), and then calculated. \\nResults: An 18 (90%) papillary carcinomas show diffuse and strong (3+ and 4+) expression of CK19 . ,three out of ten (30%) MNG were weakly positive(1+ and 2+) and focal in distribution while in follicular adenoma all cases were negative for CK19 . \\nConclusion: Ck 19 can stain benign and malignant thyroid tissue, but strong membranous staining applied in cases of papillary ca , thus can be used as confirmatorytool for PTC diagnosis.\",\"PeriodicalId\":11202,\"journal\":{\"name\":\"Diyala Journal of Medicine\",\"volume\":\"90 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diyala Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26505/djm.v24i1.972\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diyala Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26505/djm.v24i1.972","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Expression of CK19 in papillary thyroid carcinoma in comparison with benign thyroid lesions
Background: The Papillary variant of thyroid carcinoma is one of the common types of thyroid malignancies , the commonest. Its diagnosis usually is microscopic which based on nuclear features.
Objective: To assess the immunohistochemical expression of cytokeratin 19 (CK19) in PTC and compare its reactivity with other thyroid conditions to approve its importance as a useful test for diagnosing PTC.
Patients and Methods: Twenty- cases of papillary thyroid carcinoma (with different variants), five follicular adenomas and ten multinodular goiters (MNG) were collected over three years (2018-2021).10% formalin-fixed sections were collected from thyroidectomy specimens. Stained with Hematoxylin and eosin then immunohistochemical staining for immune-marker CK 19 was done using standard techniques. The results were quantitatively scored as the following: score 0 (negative ), score 1+ (<5%) positive cells), score 2+ (5- 25%), score 3+ (25-75%) ,finally score 4+ (>75%) positive cells), and then calculated.
Results: An 18 (90%) papillary carcinomas show diffuse and strong (3+ and 4+) expression of CK19 . ,three out of ten (30%) MNG were weakly positive(1+ and 2+) and focal in distribution while in follicular adenoma all cases were negative for CK19 .
Conclusion: Ck 19 can stain benign and malignant thyroid tissue, but strong membranous staining applied in cases of papillary ca , thus can be used as confirmatorytool for PTC diagnosis.